ABSTRACT
A major goal of cancer immunotherapy is to generate specific and long-lasting antitumor immune responses capable of destroying existing tumor cells and preventing subsequent disease recurrences. Immunotherapies can be generally divided into two approaches. In the first approach, agents that activate host defense cells, such as interleukin-2 (IL 2) or interferons, are used to augment host effector cell function. The second approach attempts to increase tumor immunogenicity sufficiently to induce specific host antitumor immune responses.
